# Ablatotech Signals: Putative Target Q92834 in Dry Age-Related Macular Degeneration
Background
Dry age-related macular degeneration (AMD) is a leading cause of vision loss in the elderly, characterized by the degeneration of the macula, the central part of the retina. Despite its prevalence, there are limited therapeutic options available, and the underlying molecular mechanisms remain poorly understood. In this context, the protein encoded by UniProt entry Q92834 has been identified as a putative target that warrants further investigation.
Data-mining rationale
The identification of Q92834 as a candidate target was achieved through a comprehensive cross-referencing of UniProt's reviewed human entries associated with dry AMD against six microarray datasets available in the NCBI Gene Expression Omnibus (GEO). This approach aims to uncover potential targets that have not yet been explored in clinical settings, as evidenced by the absence of Q92834 in any registered Phase 1 or higher clinical programs.
Why prior analyses may have missed this
The GEO datasets analyzed in this study were generated before the widespread adoption of advanced statistical methods such as the empirical-Bayes approach implemented in the limma package. These older analyses may have lacked the statistical power to detect significant associations, potentially overlooking Q92834 as a relevant target. By re-analyzing these datasets with limma and applying the Benjamini-Hochberg false discovery rate (FDR) correction, previously hidden associations may be revealed.
Reasoning for further validation
To substantiate the candidacy of Q92834 as a therapeutic target for dry AMD, several experimental steps are recommended:
1. **Re-analysis of GEO datasets**: Utilize limma with an FDR threshold of < 0.05 to identify top differentially-expressed genes related to Q92834.
2. **Validation in independent cohorts**: Conduct quantitative PCR (qPCR) to verify the differential expression of Q92834 in an independent cohort of dry AMD patients.
3. **Tissue specificity assessment**: Explore the expression profile of Q92834 across various tissues using resources like GTEx and the Human Protein Atlas to determine its relevance to retinal pathology.
4. **Pathway context exploration**: Employ tools such as STRING and OmniPath to map the biological pathways involving Q92834, providing insights into its functional role in dry AMD.
5. **Druggability assessment**: If validated, evaluate the druggability of Q92834 using databases like DGIdb and ChEMBL to explore potential therapeutic interventions.
These steps are crucial for establishing Q92834 as a viable target for dry AMD treatment and for guiding future drug development efforts.